Chronic obstructive pulmonary disease
Conditions
Interventions
Intervention group:This study was based on the IMB model to construct a multi-faced pharmaceutical intervention based on digital means
control group:Usual pharmaceutical care
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Be 18 years of age or older; 2.Clinically diagnosed with chronic obstructive pulmonary disease (COPD) diagnosed by a physician with a severity of grade 2 to 4 according to the GOLD pulmonary function class, and an estimated FEV1<80% after inhalation of bronchodilators (previous pulmonary function test reports can be accepted as the basis for screening); 3.Patients who have been used inhalant incorrectly in practice; 4.Voluntarily participate in this clinical study and sign a written informed consent form;
Exclusion criteria
Exclusion criteria: 1.Unable to obtain informed consent from patients or family members; 2.During pregnancy; 3.Patients with terminal disease, malignant tumor, pulmonary tuberculosis, cardiopulmonary failure, etc., and patients unable to cooperate with the pulmonary function test due to disease status; 4.According to the doctor's judgment, there are cognitive and mental impairments, severe visual, auditory, and communication impairments, as well as other situations that affect the use of inhalers; 5.Difficulty in movement, limited mobility, or other reasons, it is expected that long-term follow-up cannot be completed; 6.Participation in other pharmaceutical intervention studies; 7.Other situations where the pharmacist determines that the research subject is unable to comply with the trial plan;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| St George' s Respiratory Questionnaire, SGRQ;Medical cost; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function indicators;Annual incidence of acute exacerbation of chronic obstructive pulmonary disease;Test of Adherence to Inhalers, TAI;European Quality of Life-5 Dimensions-5 Level Version Scale;Pharmaceutical Service Questionnaire; | — |
Countries
China
Contacts
Public ContactLihong Liu
China-Japan Friendship Hospital
Outcome results
None listed